Influenza virus employs a novel mechanism for the synthesis of its viral mRNAs. Viral mRNA synthesis requires initiation by host cell primers, specifically capped (m7Gppp Nm-containing) RNA fragments derived from host cell RNA polymerase II transcripts (Plotch et al., 1979; Krug et al., , 1981 . This occurs in the nucleus of the infected cells. Viral mRNA synthesis requires the continuous functioning of the cellular RNA polymerase II, and is therefore inhibited by α-amanitin. The host cell primers are generated by a viral cap-dependent endonuclease that cleaves the capped cellular RNAs 10-13 nucleotides from their 5′ ends, preferentially at a purine residue. Priming does not require hydrogen bonding between the capped primer fragments and the 3′-ends of the viral (v)RNA templates. Rather, priming requires the presence of a 5′-methylated cap structure. In fact, each of the methyl groups in the cap, the 2′-O-methyl on the penultimate base as well as the 7-methyl on the terminal G, strongly increase priming activity. Transcription is initiated by the incorporation of a G residue onto the 3′ end of the resulting fragments, directed by the penultimate C residue of the vRNAs. Viral mRNA chains are then elongated until a stretch of 4-7 uridine residues is reached, 17 to 22 nucleotides before the 5′ ends of the vRNAs, where transcription terminates and polyadenylate is added to the mRNAs. These capped short RNA fragments are potential inhibitors of cap-dependent transcription in vitro. A recent study has confirmed earlier data (Bouloy et al., 1978; Ulmanen et al., 1981; Braam et al., 1983; Kawakami et al., 1983; Kato et al., 1985) that suggest that priming by capped oligonucleotides can be uncoupled from the endonuclease activity of the influenza RNA polymerase, and has suggested the use of such inhibitors as decoys of cap-dependent transcription in vitro (Chung et al., 1994 
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Introduction
proteins, the nucleocapsid (NP) protein and the three P (PB1, PB2 and PA) proteins (Plotch et al., 1981) . The viral RNA polymerase (PB1, PB2 and PA) and nucleoprotein genes of influenza virus A are potential targets for an antisense oligonucleotide and a decoy (cap of primer RNA) (Hay et al., 1977a,b; Robertson et al., 1981) . In previous studies, we have shown that a synthetic capped RNA with a tail as short as 13 nucleotides can be elongated by the polymerase (Hatta et al., 1998) .
In this report, we present a detailed analysis of the inhibition of influenza virus RNA polymerase gene expression by another type of 5′-capped short RNA fragment containing phosphorothioate bonds (Gms 12-15 nt), in the clone 76 cell line (Nakamura et al., 1991; Kimura et al., 1992) . Furthermore, we describe the nuclease resistance of the 5′-capped short RNA fragments containing phosphorothioate bonds.
Materials and methods

Oligonucleotide synthesis
The template oligonucleotides containing the T7 RNA polymerase promoter were synthesized by the phosphoramidite method using an Applied Biosystems Model 392 DNA/RNA synthesizer on the 1 µM scale, with controlled pore glass supports. The oligonucleotides were purified by reverse phase HPLC chromatography. The extinction coefficients of the oligonucleotides were determined by calculating the theoretical extinction coefficients as the sum of the nucleosides and multiplying with the experimentally determined enzymatic hypochromicity.
5′-Capped short RNA strand synthesis
The DNA template containing the T7 RNA polymerase promoter was annealed in a 1:1 molar ratio in 0.2 mM HEPES-KOH (pH 7.5) by heating at 95°C for 3 min, followed by snap-cooling on ice. The T7 RNA transcription reactions contained 0.6 µg DNA template, 80 mM HEPES-KOH (pH 7.5)/12 mM MgCl 2 , 2 mM spermidine, 20 mM DTT, 1.0 µg of m7GpppGm (Pharmacia Biotech), 10 mM of each NTP or [α-S]NTP, 10 mM KCl, 10 mM MgCl 2 , 20 µg/µl BSA, 40 U /µl RNasin and 7 mg/ml T7 RNA polymerase (5 µl). The reaction mixture was incubated for 2 h at 37°C. Full-length transcripts (12-15 nucleotides) were purified by 7 M urea/20% polyacrylamide gel electrophoresis (PAGE), elution and ethanol precipitation in the presence of 3 M sodium acetate.
Nuclease stability of oligonucleotides
The oligonucleotides , and the uncapped RNA 12 mer (GAAUACUCAAAC, RNA 12 mer) 0.15 A 260 ] were dissolved in 100 µl buffer (100 mM NaCl, 20 mM Tris/HCl, pH 8.0, 12 mM MgCl 2 , 12 mM CaCl 2 and 1 mMEDTA) and were incubated with nuclease BAL-31 (4 µl, 40 unit; New England BioLabs Inc (Berkerly, Mass., USA) at 37°C. Aliquots were taken at 0, 30, 60 and 240 min and were analysed by PAGE (20% polyacrylamide containing 7 M urea). Densitomeric analysis of gels was performed on a BAS-2000 (Fuji Comp. Tokyo, Japan, USA).
Cells
The murine C127 derivative cell line, clone 76 (Nakamura et al., 1991; Kimura et al., 1992) , was grown in Dulbecco′s modified Eagles medium (DMEM) supplemented with 10% fetal bovine serum (FBS).
In vitro RNA synthesis
The plasmid pOUMS101 contains the CAT gene sandwiched between the 5′-and 3′-terminal sequences of the cDNA encoding RNA segment 8 of influenza virus A/PR/8/34, in the antisense orientation of the T7 RNA polymerase (Yamanaka et al., 1991) . Transcription of Mbo II-digested pOUMS101 by T7 RNA polymerase results in the synthesis of the antisense CAT RNA. The template DNA was removed by treatment with DNase I. The RNA transcript was purified by TBE/7 M urea, 5% PAGE, elution and ethanol precipitation in the presence of 3 M sodium acetate.
RNA transcription in clone 76 cells
Clone 76 cells, grown in 60 mm dishes and approximately 50% confluent, were treated with 10 -6 M dexamethasone in DMEM containing 10% FBS at 37°C. After 24 h, the cells were washed with PBS, a mixture of 5′-capped RNA fragments and 5 µg of lipofection reagent (N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium methylsulfate, DOTAP; Boehringer Mannheim) in DMEM was added, and the cells were incubated for 4 h at 37°C. The cells were washed with PBS, and then transfected with 100 ng of antisense CAT RNA in 5 µg of DOTAP without DMEM for 4 h at 37°C. After transfection, cells were further incubated in fresh DMEM containing 10% FBS for 20 h at 37°C. The amount of CAT protein in the cells was monitored by the CAT-ELISA kit (anti-CAT-DIG; Boehringer Mannheim).
Results
The RNA-dependent RNA polymerase of influenza virus transcribes mRNA through a unique cap scavenging mechanism. The viral enzyme binds to a 'cap-1' structure (m7GpppXm) of the host mRNA, cleaves the molecule 9-15 bases downstream of the cap, and uses the 5′-capped short RNA fragments as a primer for mRNA synthesis (Rug et al., 1989; Yamanaka et al., 1991) . Viral mRNA synthesis is catalyzed by four viral proteins, the NP protein and the three P (PB1, PB2 and PA) proteins. The viral RNA polymerase PB2 of influenza virus A is a potential target for a decoy (cap of primer RNA). In fact, we have shown that the 5′-capped RNA fragments as decoys exhibited higher inhibitory effects than the antisense phosphorothioate oligonucleotide (PB2-AUG-as 20 nt long) complementary to the site of the PB2-AUG initiation codon (Hatta et al., 1998) .
To clarify the Gms chain length and its structural specificity as an inhibitor of the RNA polymerase gene expression, we tested the effects of the 5′-capped short RNA fragments containing phosphorothioate groups in the internucleotidic bonds on the RNA polymerase gene expression in clone 76 cells (Figure 1 ). The 5′-capped short RNA fragments (Gms and Gm) were introduced into the clone 76 cells by liposome-mediated transfection (Caplen et al., 1994; Logan et al., 1995; Walker et al., 1995) . The in vitro activities of these 5′-capped short RNA strands on the influenza virus RNA polymerase gene expression were assessed on the basis of their inhibition of CAT protein expression with the CAT-ELISA method.
The 5′-capped phosphodiester (Gm) and phosphorothioate (Gms) oligonucleotides (see Figure 1) were synthesized by in vitro transcription from the DNA template containing the T7 RNA polymerase promoter using T7 polymerase, NTPs or [α-S]NTPs and m7GpppGm as primers (described in Materials and methods). The T7 RNA polymerase method produced these 5′-capped oligonucleotides (Gms 12-15 and Gm 12) in 60-70% yields.
The liposomally endocapsulated 5′-capped short RNA fragments containing the phosphorothioate groups in the internucleotidic bonds, the 12-15 nt long 5′-capped RNA fragments (Gms 12, Gms 13, Gms 14 and Gms 15) had highly inhibitory effects on the influenza virus RNA polymerase gene expression, causing more than 71% inhibition at a concentration of 0.03 µM (Table 1) . Furthermore, they showed the highest inhibitory effects, causing more than 77% inhibition, at a 0.3 µM concentration. In contrast, the liposomally endocapsulated 5′-capped short RNA fragment containing the phosphodiester groups into internucleotidic bonds, the 12 nt long 5′-capped RNA fragment (Gm 12) caused 61% inhibition at a concentration of 0.03 µM. However, the 13 nt long 5′-capped RNA fragment (Gm 13) showed lower inhibitory effects at 0.03 and 0.3 µM concentrations. In the case of 5′-capped short RNA fragments, the oligomer chain length may have an effect as an inhibitor of influenza virus RNA polymerase gene expression. That is to say, the PB2 protein recognized and bound to the Gm13 as a positive strand RNA primer. The viral polymerase can efficiently bind the short capped RNAs that are less than 12 nucleotides in length, but the viral enzymes cannot utilize those RNAs as primers.
In addition, in the case of the 5′-capped short RNA strands containing the phosphorothioate groups in the internucleotidic bonds, the 13-15 nt long 5′-capped RNA fragments (Gms 13, Gms 14 and Gms 15) encapsulated The 5′-capped-phosphodiester and -phosphorothioate oligoribonucleotides are denoted by Gm and Gms, respectively. *The 5′-capped short RNA fragments (cap decoys) are described in Figure 1 . †The inhibitory effects are given as the percentage of inhibition of CAT protein expression, and are compared and normalized to 100% CAT protein expression. ‡Data represent average values for at least three different experiments.
with cationic lipid (DOTAP) showed highly inhibitory effects similar to that of the the 12 nt long 5′-capped RNA fragment, Gm 12. The chain length of the 5′-capped phosphorothioate RNA showed no significant differences in the inhibition of influenza virus RNA polymerase gene expression. Next, the nuclease sensitivities of the 12 nt long 5′-capped RNA fragments (Gms 12 and Gm 12) were studied with a 3′, 5′-exonuclease (nuclease BAL-31) (Figure 2) . The results obtained by incubating the 5′-capped phosphorothioate RNA (Gms 12) in nuclease BAL-31 provided additional evidence of their relative stability. The Gms-12 was stable after 4 h, whereas the uncapped RNA 12 mer (RNA 12 mer) was completely degraded after 30 min. On the other hand, the Gm-12 was more stable than the RNA 12 mer. This result suggests that the 5′-capped phosphorothioate RNA fragments showed greater nuclease resistance than the 5′-capped phosphodiester RNA fragments. Phosphorothioate oligonucleotides have been shown to be resistant to a number of nucleases (Shaw et al., 1991; Cummins et al., 1996) . A capped RNA with a phosphorothioate backbone could be resistant to the endonuclease activity of the influenza virus polymerase.
Discussion
The inhibition of the influenza virus polymerase with a number of organic compounds has been reported by several research groups (Tomassini, et al., 1994 (Tomassini, et al., , 1996 Hensens et al., 1995; Cianci et al., 1996) . These agents were shown to inhibit the endonuclease function of PB1 protein, presumably through direct binding to endonuclease (Li et al., 2001) .
Viral mRNA synthesis is catalyzed by viral nucleocapsids (Plotch et al., 1981) , which consist of the individual vRNAs associated with four viral proteins, the NP protein and the three P (PB1, PB2, and PA) proteins (Ulmanen et al., 1981) . The P proteins are responsible for viral mRNA synthesis, and some of their roles have been determined by analyses of in vitro reactions catalyzed by virion nucleocapsids (Ulmanen et al., 1981; Braam et al., 1983) . Primary transcription begins after the influenza virus transcriptase binds to and cleaves the host mRNA. An inhibitor based on the viral RNA polymerase (PB1, PB2 and PA) of influenza virus A would be ideal for both potency and specifcity. A few studies have investigated the inhibition of influenza virus replication in vitro and in vivo by Cap decoy as a potent inhibitors of capped-RNA primed transcription (Chung et al., 1994; Hatta et al., 1998) .
We have shown previously that the 5′-capped short phosphodiester RNA fragments, Cap decoy, (Gm 12 nt) are the inhibitors of influenza virus RNA polymerase gene expression. Here, we also investigated capped RNA derivative containing phosphorothioate oligonucleotides as a potential polymerase inhibitor. The modified 5′-capped short phosphorothioate RNA fragments (Gms 12-15 nt) with the 5′-capped structure (m7GpppGm) were synthesized by T7 RNA polymerase (Figure 1) . The 5′-capped phosphorothioate RNA fragments, the 12-15 nt long Gms encapsulated with cationic lipid (DOTAP), showed the greatest inhibition of influenza virus RNA polymerase expression compared with the 5′-capped short RNA fragments (Gm 12 nt) in clone 76 cells (Table 1) . Furthermore, the modified short RNA fragment showed greater nuclease resistance (Figure 2) . That is to say, the 5′-capped phosphorothioate RNA fragment was not cleaved by the endonuclease, probably because the influenza virus polymerase could not hydrolyze the phosphorothioate internucleotidic bonds between the bases in the RNA tail, for this capped RNA is long enough to be used as a primer. However, the unmodified capped substrates containing RNA chains of more 13 nt could be cleaved to the primer fragment (Chung et al., 1994; Hatta et al., 1998) . Therefore, there is a minimal RNA chain length of the unmodified 5′-capped RNA fragments (Gm) required for priming activity. However, the chain lengths of the 5′-capped phosphorothioate RNA (Gms) showed no signifi- cant differences in the inhibition of influenza virus RNA polymerase expression. These results suggest that inhibition of this modified RNA (Gms) is at the level of substrate binding to polymerase. Phosphorothioate oligonucleotides have been shown to block the proliferation of HIV-1 in acutely infected cells in a non-sequence specific manner (Matsukura et al., 1987) , probably by the inhibition of reverse transcriptase (Majumdar et al., 1989; Maury et al., 1992; Hatta et al., 1993) and/or the viral entry process (Stein et al., 1991; Lederman et al., 1996) . That is, these oligonucleotides can interact with nucleic acid binding protein such as transcription factors and single-strand nucleic acid binding proteins (Crooke, 1995) . The 5′-capped phosphorothioate RNA fragments (Gms) were not used as primers because the endonuclease activity cannot hydrolyze phosphorothioate linkages between the bases in the RNA tail. The present study indicates that the 5′-capped phosphorothioate short RNA fragments strands endocapsulated with cationic lipid (DOTAP) may be useful as potential therapeutic treatment for influenza A virus.
